作者
Flavio Signorelli, Gustavo Guimarães Moreira Balbi, Nadia E Aikawa, Clovis A Silva, Léonard de Vinci Kanda Kupa, Ana C Medeiros-Ribeiro, Emily FN Yuki, Sandra G Pasoto, Carla GS Saad, Eduardo F Borba, Luciana Parente Costa Seguro, Tatiana Pedrosa, Vitor Antonio de Angeli Oliveira, Ana Luisa Cerqueira de Sant’Ana Costa, Carolina T Ribeiro, Roseli Eliana Beseggio Santos, Danieli Castro Oliveira Andrade, Eloisa Bonfá
发表日期
2022/7
期刊
Lupus
卷号
31
期号
8
页码范围
974-984
出版商
SAGE Publications
简介
Objective
Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19.
Methods
This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at …
学术搜索中的文章
F Signorelli, GGM Balbi, NE Aikawa, CA Silva… - Lupus, 2022